| Price Range 12mo avg: | $2M – $2.5M |
|---|---|
| $/sf 12mo avg: | $318.75 |
| CAP Rate 12mo avg: | 7.29% |
| NOI average: | $173,700 |
| Lease Terms: | 15yrs NNN |
| Building Size avg: | 7,500 SF |
| Lot Size avg: | 2.5+/- acres |
Fresenius is a global health care group with products and services for dialysis, the hospital and the medical care of patients at home.
The Fresenius Group consists of the following four business segments that are responsible for their own business operations worldwide: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed.
Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS)
Fresenius Medical Care is the world’s largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.7 million individuals worldwide. Through its network of 3,361 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 286,312 patients around the globe. Fresenius Medical Care is also the world’s leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
| S&P Credit Rating: | BBB- |
|---|---|
| Moody’s Credit Rating: | Ba1 |
| Annual Revenue 2014: | $15.8B |
| Annual Revenue 2013: | $14.6B |
| Revenue Growth: | ↑ 8% from 2013 |
| Net Income | $1.05B |
| Units (Dec. 2014) | 3,361 |
| Average Units Volume: | $4.7M |
Yahoo! Finance: FMS News Latest Financial News for FMS
-
DaVita’s Valuation on September 17
on September 17, 2018 at 3:45 pm
DaVita (DVA) is a biotechnology company focused on the discovery, development, and commercialization of specialist medicines to cater to the medical needs in rare diseases and other specialized conditions. DaVita reported non-GAAP EPS of $1.15 on revenues of $2.9 billion, a 6.9% growth YoY (year-over-year) compared to $2.7 billion in the second quarter of 2017. […]
-
Better Buy: Cara Therapeutics Inc. vs. Fresenius Medical Care AG & Co.
on September 13, 2018 at 12:45 pm
Which stock wins in a one-on-one matchup between these two partners? […]
-
Kidney Care Demand Shoots Up in US: 3 Stocks Likely to Gain
on September 6, 2018 at 1:38 pm
As the U.S. dialysis industry has been garnering huge profits for decades, some dialysis stocks are worth a look. […]
-
California bill capping dialysis profits advances, hitting company stocks hard
on August 31, 2018 at 2:16 pm
MARKET PULSE A California bill that would significantly affect dialysis revenues for companies like DaVita Inc. (DVA) and Fresenius Medical Care AG & Co. (FMS) passed the state assembly and senate this week. […]
-
Has Fresenius Medical Care AG & Co KGaA’s (ETR:FME) Earnings Momentum Changed Recently?
on August 21, 2018 at 12:17 pm
In this article, I will take a look at Fresenius Medical Care AG & Co KGaA’s (ETR:FME) most recent earnings update (30 June 2018) and compare these latest figures againstRead More... […]
NYSE: FMS
